Edit

5AM Ventures

https://5amventures.com
Last activity: 23.05.2024
Active
Invests in categories: MedtechHealthTechBioTechTechnologyDrugResearchDevelopmentProductPlatformDelivery
5AM was founded in 2002 and pursues investments in advanced life science innovations, and seeks to be diversified across the biopharmaceutical therapeutics, and platform technologies. Within each sector, 5AM invests across multiple therapeutic areas and modalities and evaluates opportunities based on innovative platform technologies, corporate spin-offs and products with shorter development cycles.

Content 5AM shares on this platform is not, and may not be relied on, in any manner, as legal, tax, investment, accounting or other advice or as an offer to sell or a solicitation of an offer to buy an interest in any private fund, special purpose or other investment vehicle sponsored by 5AM Ventures. Content 5AM shares on this platform is not an investment recommendation.

For a full list of all 5AM portfolio companies, please visit: https://5amventures.com/portfolio/
Followers
11.85K
News
958
Portfolio
74
Mentions
80
Location: United States, California, San Francisco
Employees: 11-50
Founded date: 2002
Investment Type: Venture Capital
Investment Stage: Series A; Series B; Series C; Grant

Portfolio 74

DateNameWebsiteTotal RaisedLocation
18.10.2023Precede Bi...precede.bio$57MUnited Sta...
17.09.2023Skye Biosc...skyebioscience.com-United Sta...
17.05.2023Nido Bionidobio.com-United Sta...
23.06.2022Magnetic I...magneticinsight.com$44.1MUnited Sta...
21.06.2022Dianthus T...dianthustx.com$100MUnited Sta...
25.11.2021GlycoEra A...glycoera.com$49.74M-
25.11.2021Radionetic...radionetics.com$82.5MUnited Sta...
16.06.2021Camp4camp4tx.com$175MUnited Sta...
17.05.2021Soteriasoteriabiotherapeutics.com$42MUnited Sta...
14.04.2021Halio, Inc...halioinc.com$170M-
Show more

News 958

DateTitleDescription
21.09.2022NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249-
20.09.2022IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares-
20.09.2022Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201, a HER2-Targeted CAR-NK for the Treatment of Solid Tumors-
20.09.2022Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis-
15.09.2022IDEAYA Announces Proposed Public Offering of Common Stock-
13.09.2022Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss-
13.09.2022Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes-
13.09.2022Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza-
12.09.2022IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma-
12.09.2022Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress-
Show more

Mentions in press and media 80

DateTitleDescription
23.05.2024Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabsVenture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs 23.05.2024 12:30, Rita Longobardi linkedIn facebook twitter instagram youtube --> In mid-May, the ten V...
03.05.2024Karius Revolutionizes Infectious Disease Diagnostics with $100M Funding BoostKarius, a genomic diagnostics powerhouse, has secured a whopping $100 million in Series C funding to expand its groundbreaking Karius Test. This test, a game-changer in infectious disease diagnosis, uses cutting-edge genomic analysis and AI...
02.05.2024Karius Raises $100M in Series C FundingKarius, Inc., a Redwood City, CA-based leader in genomic diagnostics for infectious disease, raised $100m in Series C funding. The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare. Also investing was n...
02.05.2024Karius Secures $100M to Expand Non-Invasive Pathogen Blood TestWhat You Should Know: – Karius®, a leader in genomic diagnostics for infectious disease, announced today the closing of a $100 million Series C funding round. – Co-led by Khosla Ventures and newcomers 5AM Ventures and Gilde Healthcare, the ...
14.11.2023Nouscom raises CHF65 million in oversubscribed Series C financing round
23.10.2023Which VCs are investing in rare diseases?Firms include Chiesi Ventures, Frazier Healthcare Partners, OrbiMed, and Atlas Venture In the United States alone 25 million people suffer from rare disease, a number that jumps to 400 million people globally. While 1 in 10 people will suff...
07.04.2022A-Rod-backed sports betting app Mojo wants to let you bet on athletes like stocksThis is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Good morning, Term Sheeters. Jackson Fordyce here, filling in for Jessica. Paid Content How North...
06.04.2022Rough biotech market won't stop 5AM Ventures' new $750M life science fundsIt’s a good time to be 5AM Ventures—and, evidently, a biotech looking for funding. The firm just closed two life science funds totaling $750 million even as the biotech sector as a whole struggles to gain its feet in a tumultuous market. De...
04.04.20225AM Ventures Closes $750 Million Across Two Life Science Funds and Announces Team Additions-
12.11.2021GycoEra seals series A financing round at CHF 45 million
Show more

Reviews 0

Sign up to leave a review

Sign up Log In